Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers during Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Vonoprazan (Primary) ; Lansoprazole
- Indications NSAID-induced ulcer
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 07 Oct 2017 Primary endpoint (Recurrence rate of gastric or duodenal ulcer within 24 weeks) has been met as per the results published in the Gut
- 07 Oct 2017 Results published in the Gut
- 07 May 2014 According to a Takeda media release, the results of this trial will be presented at the Digestive Disease Week 2014.